Biocon has informed about a notification as follows: ‘Biocon Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA), for our vertically integrated, complex drug product Tacrolimus capsule 0.5mg, 1mg and 5mg strengths, in South Africa. This is the Company’s first approval in this Country. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.’ The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
